Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25

References

• Lanier LL, Phillips JH, Hackett J, Tutt, M, and Kumar V. Natural killer cells: Definition of a cell type rather than a function. J Immunol. 1986;137:2735-39.
   PubMed Web of Science ®Google Scholar
• Badgwell B, Parihar R, Magro C, Dierksheide J, Russo T, and Carson WE 3rd. Natural killer cells contribute to the lethality of a murine model of Escherichia coli infection. Surgery. 2002;132:205-12.https://doi.org/10.1067/msy.2002.125311
   PubMed Web of Science ®Google Scholar
• Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, R. Biassoni MC, and Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 2001;19:197-223.https://doi.org/10.1146/annurev.immunol.19.1.197
   PubMed Web of Science ®Google Scholar
• Lanier LL. NK cell receptors. Annu Rev Immunol. 1998;16:359-93.https://doi.org/10.1146/annurev.immunol.16.1.359
   PubMed Web of Science ®Google Scholar
• Lanier0 LL. NKG2D Receptor and Its Ligands in Host Defense. Cancer Immunol. Res. 2015;3:575-82.https://doi.org/10.1158/2326-6066.CIR-15-0098
   PubMed Web of Science ®Google Scholar
• Hallett WH, and Murphy WJ. Positive and negative regulation of Natural Killer cells: Therapeutic implications. Semin Cancer Biol. 2006;16:367-82.https://doi.org/10.1016/j.semcancer.2006.07.003
   PubMed Web of Science ®Google Scholar
• Kim S, Iizuka K, Aguila HL, Weissman IL, and Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A. 2000 97:2731-6.https://doi.org/10.1073/pnas.050588297
   PubMed Web of Science ®Google Scholar
• Leibson PJ. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity. 1997;6:655-61.https://doi.org/10.1016/S1074-7613(00)80441-0
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, and Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443-6.https://doi.org/10.1038/74704
   PubMed Web of Science ®Google Scholar
• Parihar, R., Dierksheide J, Hu Y, and Carson WE. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest. 2002;110:983-92.https://doi.org/10.1172/JCI0215950
   PubMed Web of Science ®Google Scholar
• Jaime-Ramirez, AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, Parihar R, Karpa V, Papenfuss TL, LaPerle KM, et al. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol. 2011;186:3401-09.https://doi.org/10.4049/jimmunol.1000328
   PubMed Web of Science ®Google Scholar
• Roda, JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, and Carson WE. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res. 2007;13:6419-28.https://doi.org/10.1158/1078-0432.CCR-07-0865
   PubMed Web of Science ®Google Scholar
• Parihar, R., Nadella P, Lewis A, Jensen R, De Hoff C, Dierksheide JE, VanBuskirk AM, Magro CM, Young DC, Shapiro CL, et al. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res. 2004;10:5027-37.https://doi.org/10.1158/1078-0432.CCR-04-0265
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab, TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, and Carson WE. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther. 2009;8:2983-91.https://doi.org/10.1158/1535-7163.MCT-09-0820
   PubMed Web of Science ®Google Scholar
• Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, and Fehniger TA. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol. Blood Marrow Transplant. 2014;20:463-73.https://doi.org/10.1016/j.bbmt.2014.01.006
   PubMed Web of Science ®Google Scholar
• Smith KA. The interleukin 2 receptor. Adv. Immunol. 1988;42:165-79.https://doi.org/10.1016/S0065-2776(08)60844-5
   PubMed Web of Science ®Google Scholar
• Waldmann TA. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 2006;6:595-601.https://doi.org/10.1038/nri1901
   PubMed Web of Science ®Google Scholar
• Lee SH, Fragoso MF, and Biron CA. Cutting edge: a novel mechanism bridging innate and adaptive immunity: IL-12 induction of CD25 to form high-affinity IL-2 receptors on NK cells. J. Immunol. 2012;189:2712-6.https://doi.org/10.4049/jimmunol.1201528
   PubMed Web of Science ®Google Scholar
• Kondadasula, SV, Roda JM, Parihar R, Yu, J, Lehman A Caligiuri MA, Tridandapani S, Burry RW, and Carson WE 3rd. Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma. Blood. 2008:111:4173-83.https://doi.org/10.1182/blood-2007-01-068908
   PubMed Web of Science ®Google Scholar
• Martin del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, et al. The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. J Immunol. 2015:195:1995-2005.https://doi.org/10.4049/jimmunol.1400084
   PubMed Web of Science ®Google Scholar
• Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, and Caligiuri MA. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur. J. Immunol. 2001;31:3016-25.https://doi.org/10.1002/1521-4141(2001010)31:10%3c3016::AID-IMMU3016%3e3.0.CO;2-J
   PubMed Web of Science ®Google Scholar
• Rajeevan MS, Ranamukhaarachchi DG, Vernon SD, and Unger ER. Use of real-time quantitative PCR to validate the results of cDNA array and differential display PCR technologies. Methods. 2001;25:443-51.https://doi.org/10.1006/meth.2001.1266
   PubMed Web of Science ®Google Scholar
• Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, et al. NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines. Cancer Immunol. Res. 2016;4:323-36.https://doi.org/10.1158/2326-6066.CIR-15-0168
   PubMed Web of Science ®Google Scholar
• Mirjačić Martinović K, Babović N. Džodić R, Jurišić V, Matković S, and Konjević G. Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients. J. Transl. Med. 2015;13:120.https://doi.org/10.1186/s12967-015-0479-z
   PubMed Web of Science ®Google Scholar
• Luedke E, Jaime-Ramirez AC, Bhave N,Roda J, Choudhary MM, Kumar B, Teknos TN, and Carson WE. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery. 2012;152:431-40.https://doi.org/10.1016/j.surg.2012.05.035
   PubMed Web of Science ®Google Scholar
• Paolini R, Bernardini G, Molfetta R, and Santoni A. NK cells and interferons. Cytokine Growth Factor Rev. 2015;26:113-20.https://doi.org/10.1016/j.cytogfr.2014.11.003
   PubMed Web of Science ®Google Scholar
• Campbell AR, Regan K, Bhave N, Pattanayak A, Parihar R, Stiff AR, Trikha P, Scoville SD, Liyanarachchi S, Kondadasula SV, et al. Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12. BMC Med Genomics. 2015;8:66.https://doi.org/10.1186/s12920-015-0142-9
   PubMed Web of Science ®Google Scholar
• Becknell B, and Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv. Immunol. 2005;86:209-39.https://doi.org/10.1016/S0065-2776(04)86006-1
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, and Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J. Exp. Med. 1984;160:1147-69.https://doi.org/10.1084/jem.160.4.1147
   PubMed Web of Science ®Google Scholar
• Caligiuri MA. Human natural killer cells. Blood. 2008;112:461-9.https://doi.org/10.1182/blood-2007-09-077438
   PubMed Web of Science ®Google Scholar
• Nagler A, Lanier LL, and Phillips JH. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J. Exp. Med. 1990;171:1527-33.https://doi.org/10.1084/jem.171.5.1527
   PubMed Web of Science ®Google Scholar
• Farag SS, and Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006;20:123-37.https://doi.org/10.1016/j.blre.2005.10.001
   PubMed Web of Science ®Google Scholar
• Caligiuri MA. Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Semin. Oncol. 1993;20:3-10.
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, and Caligiuri MA. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: A potential new link between adaptive and innate immunity. Blood. 2003. 101:3052-57.https://doi.org/10.1182/blood-2002-09-2876
   PubMed Web of Science ®Google Scholar
• Bihl F, Germain C, Luci C, and Braud VM. Mechanisms of NK cell activation: CD4(+) T cells enter the scene. Cell. Mol. Life Sci. 2011;68:3457-67.https://doi.org/10.1007/s00018-011-0796-1
   PubMed Web of Science ®Google Scholar
• Horowitz, A, Behrens RH, Okell L, Fooks AR, and Riley EM. NK cells as effectors of acquired immune responses: Effector CD4+ T cell-dependent activation of NK cells following vaccination. J. Immunol. 2010;185:2808-18.https://doi.org/10.4049/jimmunol.1000844
   PubMed Web of Science ®Google Scholar
• Gasteiger G, Hemmers S, Firth MA, Le Floc'h A, Huse M, Sun JC, and Rudensky AY. IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J. Exp. Med. 2013;210:1167-78.https://doi.org/10.1084/jem.20122462
   PubMed Web of Science ®Google Scholar
• Bernstein ZP, Porter MM, Gould M, Lipman B, Bluman EM, Stewart CC, Hewitt RG, Fyfe G, Poiesz B, and Caligiuri MA. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood. 1995;86:3287-94.
   PubMed Web of Science ®Google Scholar
• Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, and Rosenberg S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113:293-301.https://doi.org/10.1002/cncr.23552
   PubMed Web of Science ®Google Scholar
• Su EW, Moore CJ, Suriano S, Johnson CB, Songalia N, Patterson A, Neitzke DJ, Andrijauskaite K, Garrett-Mayer E, Mehrotra S, et al. IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci. Transl. Med. 2015;7:311ra170.https://doi.org/10.1126/scitranslmed.aac8155
   PubMed Web of Science ®Google Scholar
• Pachella LA, Madsen LT, and Dains JE. The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma. J. Adv. Pract. Oncol. 2015;6:212-21.
   PubMedGoogle Scholar
• Rosalia RA., Arenas-Ramirez N, Bouchaud G, Raeber ME, and Boyman O. Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. Curr. Opin. Chem. Biol. 2014;23:39-46.https://doi.org/10.1016/j.cbpa.2014.09.006
   PubMed Web of Science ®Google Scholar
• Gubbels JAA, Gadbaw B, Buhtoiarov IN, Horibata S, Kapur AK, Patel D, Hank JA, Gillies SD, Sondel PM, Patankar MS, et al. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. Cancer Immunol. Immunother. 2011;60:1789-800.https://doi.org/10.1007/s00262-011-1072-9
   PubMed Web of Science ®Google Scholar
• Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P, et al. 2012. Exploiting a natural conformational switch to engineer an interleukin-2 “superkine”. Nature. 484: 529-33.https://doi.org/10.1038/nature10975
   PubMed Web of Science ®Google Scholar
• Stegmann KA, De Souza JB, and Riley EM. IL-18-induced expression of high-affinity IL-2R on murine NK cells is essential for NK-cell IFN-γ production during murine Plasmodium yoelii infection. Eur. J. Immunol. 2015;45:3431-40.https://doi.org/10.1002/eji.201546018
   PubMed Web of Science ®Google Scholar
• Anegón I, Cuturi MC, Trinchieri G, and Perussia B. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J. Exp. Med. 1988;167:452-72.https://doi.org/10.1084/jem.167.2.452
   PubMed Web of Science ®Google Scholar
• Márquez ME, Millet C, Stekman H, Conesa A, Deglesne PA, Toro F, De Sanctis J, and Blanca I. CD16 cross-linking induces increased expression of CD56 and production of IL-12 in peripheral NK cells. Cell. Immunol. 2010;264:86-92.https://doi.org/10.1016/j.cellimm.2010.05.002
   PubMed Web of Science ®Google Scholar